Composition and method for cancer treatment
Anti-CEACAM6 antibodies and antibody fragments, nucleic acids encoding them, methods of their manufacture, and methods to treat cancer using these compounds are provided.
1. A method of treating pancreatic cancer, gastrointestinal cancer, lung cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancers, colorectal cancer, and/or stomach cancer, comprising administering an effective amount of an anti-CEACAM6 antibody or antibody fragment thereof comprising all six of the CDRs of monoclonal antibody 13.1 to a patient with pancreatic cancer, gastrointestinal cancer, lung cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancers, colorectal cancer, and/or stomach cancer, wherein the antibody or antibody fragment induces apoptosis in cancer cells.
2. The method of claim 1 , wherein the antibody or antibody fragment thereof induces apoptosis against cancer cells in the Cellular Cytotoxicity Assay described herein.
3. The method of claim 1 , which is a method of treating pancreatic cancer.
4. The method of claim 1 , which is a method of treating gastrointestinal cancer.
5. The method of claim 1 , which is a method of treating lung cancer.
6. The method of claim 1 , which is a method of treating breast cancer.
7. The method of claim 1 , which is a method of treating cervical cancer.
8. The method of claim 1 , which is a method of treating uterine cancer.
9. The method of claim 1 , which is a method of treating ovarian cancers.
10. The method of claim 1 , which is a method of treating colorectal cancer.
11. The method of claim 1 , which is a method of treating stomach cancer.
12. The method of claim 1 , wherein the antibody or antibody fragment thereof is humanized.
13. The method of claim 1 , wherein the antibody or antibody fragment thereof is chimeric.
14. The method of claim 1 , wherein said antibody or antibody fragment thereof is an antibody fragment, and the antibody fragment is an ScFv.
15. The method of claim 14 , wherein the ScFv is murine or humanized.
16. The method of claim 1 , wherein the patient is a human or a non-human animal.
17. The method of claim 1 , wherein the patient is a human.
18. The method of claim 17 , wherein the antibody or antibody fragment thereof is administered parenterally, intraperitoneally, intravenously, subcutaneously, orally, nasally, via inhalation or rectally.
19. The method of claim 1 , wherein the antibody or antibody fragment thereof is administered intravenously at a dosage of from 5 mg/m 2 to 2000 mg/m 2 .
20. The method of claim 1 , wherein the antibody is monoclonal antibody 13.1.